GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma

NCT07209813 | Not Yet Recruiting Phase 2

• 1 other identifier: 2023LP02333
• Study Type: interventional
• Target: 48
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a Phase II, open-label, randomized, multicenter study to evaluate the efficacy and safety of GKL-006 combine with TACE in adult patients with unresectable Hepatocellular carcinoma.

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular carcinoma

Outcome Measures

Primary Outcomes (1)

• Objective Response Rate

  From enrollment to the end of treatment at 6 month

Study Arms (2)

GKL-006

EXPERIMENTAL

Experimental group: GKL-006（3.0±0.9）×108 iNKT cells/m2)+TACE

Biological: GKL-006

TACE

ACTIVE COMPARATOR

TACE

Biological: GKL-006

Interventions

GKL-006 BIOLOGICAL

GKL-006（3.0±0.9）×108 iNKT cells/m2 IV single infusion on Day 1 of each 14-day cycle for up to 11 cycles (≈6 month) in the absence of disease progression or unacceptable toxicity.

GKL-006; TACE

Eligibility Criteria

• Age: 18 Years - 75 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be willing and able to provide written informed consent/assent for the trial 2.Male or female, ≥ 18 years of age, ≤ 75 years of age. 3.Hepatocellular carcinoma confirmed as unresectable by histopathology/cytology/imaging studies (such as dynamic CT or MRI) 4. With a total tumor volume not exceeding 50% of the liver, a maximum diameter of a single tumor not exceeding 7 cm, and a total number of target lesions and non-target lesions not exceeding 10 5.Patients must have at least one measurable lesion by mRECIST criteria. 6.Have an overall Child-Pugh score ≤9 7.Have a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale 8.Have life expectancy of ≥ 6 months. 9.The subject has adequate hematological and organ function, and the laboratory test results within 14 days before randomization

You may not qualify if:

• Subjects with a history of (within 5 years) or concurrent other untreated malignant tumors, except for cured basal cell carcinoma of the skin, carcinoma in situ, and breast cancer that has been recurrence-free for more than 3 years after completing radical resection.
• Have previous organ transplantation 3.Known fibrolamellar HCC or mixed hepato-cholangiocarcinoma. 4. Patients receive radiotherapy within the 4 weeks preceding study enrolment;Patients receive Chinese traditional medicine for cancer treatment within the 2 weeks preceding study enrolment; 5. Patients must not have had any surgical procedure requiring hospitalization and administration of general anesthesia within the past 4 weeks.
• \. Patients with autoimmune disease. 7.Have serious illnesses including, but not limited to, congestive heart failure (NYHA class III or IV functional classification);Left Ventricular Ejection Fraction (LVEF) \< 50% on echocardiogram;life threatening cardiac arrhythmia; or myocardial infarction or cerebral vascular accident within the last 6 months.
• \. Uncontrolled high blood pressure (systolic blood pressure, SBP ≥140 mmHg and/or diastolic blood pressure, DBP ≥90 mmHg).
• \. Has a known history of Human Immunodeficiency Virus (HIV,Syphilis,or other). 10. Pregnant or breast-feeding. 11. Has received a live vaccine within the 4 weeks preceding study enrolment; 12. Has participated in other clinical studies within the 4 weeks preceding study enrolment; 13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Principal Investigator (PI).

Sponsors & Collaborators

• Beijing Gene Key Life Technology Co., Ltd: lead

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 29, 2025
• First Posted: October 7, 2025
• Study Start: October 12, 2025
• Primary Completion (Estimated): October 31, 2026
• Study Completion (Estimated): October 31, 2026
• Last Updated: October 7, 2025

Record last verified: 2025-09